retatrutide vial of unapproved peptide had double the strength indicated on label Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

This patch helps suppress hunger and maintain energy levels, making fasting windows more manageable and sustainable

FDA-approved prescribing information for semaglutide and tirzepatide both indicate use "as an adjunct to a reduced-calorie diet and increased physical activity."What's been missing is the actuarial proof

Retatrutide and pregnancy: 24.2% average weight loss

PlexusDx explores the science behind weight maintenance, genetic factors that influence regain risk, and practical long-term strategies to protect your results